

Dissecting the Decision: Investigators Discuss the Available Data and Clinical Factors That Shape the Management of Gastrointestinal Cancers

THE CORRECT ANSWER IS INDICATED WITH YELLOW HIGHLIGHTING.

- Data suggest a lack of activity of EGFR antibodies as initial therapy for patients with CRC whose primary tumors originated on the _____ side of the colon.
 - Left
 - Right
 - Neither a nor b
- Data reported from the Phase III RECURSE trial of TAS-102 versus placebo for patients with refractory CRC demonstrated the onset of _____ to be a correlate of treatment response in patients who received TAS-102.
 - Diarrhea
 - Hand-foot syndrome
 - Neutropenia
- What is the approximate incidence of HER2-amplified mCRC?
 - 5%
 - 20%
 - 40%
- Interim data presented by Hurwitz and colleagues at the 2017 Gastrointestinal Cancers Symposium on the MyPathway trial evaluating pertuzumab and trastuzumab reported this chemotherapy-free regimen to be active in patients with heavily pretreated HER2-amplified CRC.
 - True
 - False
- Which of the following is the mechanism of action of PEGPH20?
 - Anti-PD-1/PD-L1 antibody
 - MEK inhibitor
 - Recombinant human hyaluronidase enzyme
- A recent study published in *The New England Journal of Medicine* and subsequently updated at ASCO 2016 demonstrated that patients with _____ CRC experienced objective responses to treatment with the immune checkpoint inhibitor pembrolizumab.
 - Mismatch repair (MMR) proficient
 - MMR deficient
 - Both a and b
- MEK inhibitors may increase infiltration of CD8-positive T cells into tumors, which is the biologic rationale for combining them with anti-PD-1/PD-L1 checkpoint inhibitors for patients with microsatellite-stable mCRC.
 - True
 - False
- The Phase III NAPOLI-1 trial evaluating nanoliposomal irinotecan (nal-IRI) with or without 5-FU/LV versus 5-FU/LV alone for patients with metastatic pancreatic cancer after disease progression on gemcitabine-based therapy _____ a clinical benefit with the addition of nal-IRI to 5-FU/LV compared to 5-FU/LV alone.
 - Demonstrated
 - Did not demonstrate
- Napabucasin (BBI608) is a _____ under evaluation in combination with chemotherapy for patients with advanced gastric cancer and other solid tumors.
 - Anti-PD-1/PD-L1 inhibitor
 - Cancer stemness inhibitor
 - VEGF inhibitor
- Patients with advanced HCC and disease progression on sorafenib treated with regorafenib on the Phase III RESORCE trial _____ experience a benefit as compared to those who received placebo.
 - Did
 - Did not